22 results about "Atropine" patented technology

Provided is a method for producing a solution of atropine with improved recovery. A method for producing a solution of atropine-211, comprising the steps of: irradiating bismuth with alpha rays, generating atropine-211 in the bismuth, and distilling the bismuth irradiated with the alpha rays, separating and purifying atropine-211, and dissolving it in an aqueous sodium bicarbonate solution.

The invention discloses an atropine derivative and a preparation method and application thereof, and belongs to the technical field of medical preparations, the atropine derivative and a salt or a pharmaceutical composition thereof can be used as a ciliary muscle paralysis agent and / or a mydriasis agent; the choroid and sclera functions can be regulated and controlled by improving choroid microcirculation and sclera hypoxia environment, inhibiting an HIF-1alpha signal channel and directly targeting sclera fibroblasts to inhibit extracellular matrix generation and remodeling; the medicine is used for relieving muscae volitantes symptoms; amblyopia, lazy eye diseases or myopia can be relieved; for treating or preventing myopia; the traditional Chinese medicine composition has good maintenance time and treatment effect, can obviously reduce the use frequency and use amount, improves the use experience, and reduces the medicine use cost.

The invention relates to an application of atropine (Atropine, C17H23NO3) in preparation of a medicine for treating sleep disorder. Existing sleep drugs are generally ineffective to sleep disorders related to circadian rhythm and cannot restore a normal sleep-awakening period for many patients, and benzodiazepine and non-benzodiazepine hypnotics have significant side effects such as dependency, cognitive disorder and dizziness, and long-term use of the drugs is limited. According to the invention, a per3 gene defect zebrafish model is used for drug screening, and a new application of a clinically used drug, namely atropine, in preparation of drugs for treating sleep disorders is provided for the first time, especially for treating sleep disorders which are insensitive to existing sedative drugs or are related to circadian rhythm disorder, and particularly for treating sleep disorders which are not sensitive to existing sedative drugs or are related to circadian rhythm disorder, circadian rhythm disorder, circadian rhythm disorder and circadian rhythm disorder. The optimal curative effect can be achieved in the indication by 12 mu M, the sleep-awakening cycle disorder caused by Per3 defects is improved, and the normal sleep-awakening cycle is recovered.

The invention discloses an atropine myopia prevention and control evidence-based dialogue method and system, and belongs to the technical field of prevention and control data intelligence. The method comprises the steps of question analysis: performing semantic analysis on a received user question; retrieval of evidence-based evidences: performing retrieval enhancement according to a semantic analysis result, and obtaining the evidence-based evidences and sources and levels of the evidence-based evidences from the atropine myopia prevention and control knowledge graph; inference chain generation: combining evidence-based evidences with cues, and guiding the model to generate inference chain content according to the steps of individual core feature analysis, atropine prevention and control scheme matching, safety evaluation and scheme optimization through a thinking chain CoT; and answer generation: according to the evidence-based evidence and the reasoning chain content, generating different types of atropine myopia prevention and control answers. According to the method and the device, the matching between each core entity in the output atropine myopia prevention and control scheme and individual requirements is improved, and the accuracy of the atropine myopia prevention and control scheme is improved.

A liquid ophthalmic composition comprising atropine or a pharmaceutically acceptable salt thereof, at least one buffering agent and at least one tonic agent, wherein Atropine or a pharmaceutically acceptable salt thereof is present in the composition in an amount of 0.001% to 0.1% by weight. that at least one buffering agent is present in the composition at a concentration of 0.5 mM to 50 mM, that at least one tonic agent is present in the composition at a concentration of 100 mM to 500 mM, the composition has a pH value of 4.0 to 6.0.

The present invention provides an aqueous pharmaceutical composition for the treatment of myopia, prevention of myopia and / or suppression of myopia, comprising atropine or a salt thereof in a concentration of 0.025% (w / v), wherein the aqueous pharmaceutical composition is administered to a myopic patient aged 12 to 15 years.

Gel, ointment, lotion, or cream formulations containing an active pharmaceutical ingredient including a tropanil portion are provided herein. The gel, lotion, or cream formulations may contain at least one low molecular weight (LMW) compound or a pharmaceutically acceptable salt thereof. Also provided herein are gel, ointment, lotion, or cream formulations containing active pharmaceutical ingredients such as atropine, pilocarpine, physostigmine, or travoprost.

The present disclosure is directed, in part, to aqueous pharmaceutical solutions comprising benzyl atropine or a pharmaceutically acceptable salt or prodrug thereof, at least one buffer, at least one tonicity agent, and at least one solubilizing agent, processes of preparing an aqueous solution comprising benzyl atropine, the products of such processes, and methods of preventing myopia, treating myopia, reducing myopia progression, or preventing myopia progression in a subject in need thereof, by administering to the eye of the subject a therapeutically effective amount of such an aqueous pharmaceutical solution.

Ophthalmically-acceptable formulations of atropine and other muscarinic acetylcholine receptor antagonists are provided that can be heat-sterilized without significant degradation of the muscarinic acetylcholine receptor antagonist. The formulations are less acidic than prior muscarinic acetylcholine receptor antagonist ophthalmic formulations, making them more comfortable when administered to the eye.

The application belongs to the field of medicine, and provides atropine salt, a preparation method thereof, a pharmaceutical composition and application. The atropine salt derivative prepared in the application has high activity in the preparation of eye drugs, and has high stability. The compound has good mydriatic effect. The atropine salt derivative prepared in the application has high solubility and stability, and has significant advantages in the preparation of eye drugs and application.

The present application provides compositions, methods, and dispensers for topical delivery of ophthalmological active pharmaceutical ingredients (APIs).In one example, a composition is provided comprising an active pharmaceutical ingredient soluble in MCT wherein the API is not atropine or a salt thereof, a medium chain triglyceride (MCT); and a semi-fluorinated alkane compound. In another example, a nano-emulsion is provided comprising about an active pharmaceutical ingredient soluble in MCT; a medium chain triglyceride (MCT); and a semi-fluorinated alkane compound, wherein the nano-emulsion has a droplet particle size D90 of less than about 100 nm. Dispensers containing the compositions are also provided and include glass and polyethylene terephthalate dispensers or containers. Methods of using the compositions are also provided and include a method for treating an ocular condition in a subject comprising administering the compositions or nano-emulsions to an eye of the subject.The present application also provides compositions and methods for treating ophthalmological conditions such as presbyopia and glaucoma. The compositions can comprise a muscarinic cholinergic receptor agonist and a semi-fluorinated alkane compound; or can comprise a muscarinic cholinergic receptor agonist, a semi-fluorinated alkane compound, and an organic cosolvent. The compositions can confer chemical stability of the muscarinic cholinergic receptor agonist.

To provide a medicine that exhibits effects such as improving myopia and suppressing the progression of myopia in young patients. [Solution] An aqueous pharmaceutical composition for the treatment, prevention and / or inhibition of myopia, comprising a 0.025% (w / v) concentration of atropine or a salt thereof, characterized in that it is used to be administered to myopic patients aged 12 to 15 years.

Disclosed herein is an aqueous composition comprising 0.001-0.1% (w / v) atropine or a salt thereof, a water-soluble polymer, and buffer (I), which is at a pH range of 6 or lower, wherein the buffer (I) is at least one selected from the group consisting of a phosphate buffer, an aminocarboxylate buffer, a carbonate buffer, an acetate buffer, a tartrate buffer, a borate buffer, and trometamol.

The invention belongs to the technical field of biological medicines, and relates to atropine-carrying responsive disintegrating nanoparticles, a preparation method and application of the atropine-carrying responsive disintegrating nanoparticles in myopia treatment. In particular to an atropine-loaded responsiveness disintegrating nanoparticle, a preparation method of the nanoparticle and a method for treating myopia through precise space-time regulation and control on a sclera fibroblast microenvironment. The invention firstly provides a targeted ROS responsive disintegration nanoparticle, the nanoparticle takes Zn < 2 + > as a center and reacts with a ligand H2L to form a spherical nanoparticle through self-assembly, and L represents C11H18O4S < 2->.

Myopia progression is safely and effectively reduced by topical administration of a storage-stable low-dose formulation in which atropine is present at a concentration of 0.01%. Unexpectedly, such formulation was proven more effective to reduce myopia progression as compared to an otherwise identical formulation containing 0.02% atropine. For example, formulations with an atropine concentration of about 0.01% slowed down myopia progression as compared to subjects not receiving treatment.

The present invention belongs to the field of pharmaceutical formulations, and specifically relates to an atropine pharmaceutical composition, comprising an atropine pharmaceutically acceptable salt, a sulfonic acid-based cation exchange resin, and a suspending agent. The suspending agent is selected from one or more of carbomer, povidone, and hydroxyethyl cellulose. The formulation of the atropine pharmaceutical composition of the present invention can significantly reduce the content of free atropine in a medicinal solution and thus can control the content of related substances within a relatively low range, so that the drug has superior stability at room temperature and a superior drug release effect.

The present invention provides aqueous pharmaceutical compositions for the treatment, prevention, and / or inhibition of the progression of myopia. [Solution] An aqueous pharmaceutical composition containing atropine or a salt thereof at a concentration of 0.025% (w / v), characterized in that it is used for administration to myopic patients aged 12 to 15 years.

The invention relates to a compound atropine composition as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention provides a compound atropine composition, which comprises a side effect antagonist and 0.02-0.1 wt% of atropine, the mass ratio of atropine to side effect antagonist is atropine: side effect antagonist = 1: (0.01-500), and atropine comprises at least one of an atropine monomer, a pharmaceutically acceptable salt of atropine and an atropine derivative. The side effect antagonist and the atropine are matched to form the compound atropine composition, so that the side effects (such as photophobia, pupil distension and the like) caused by the atropine in the myopia control process can be effectively improved, and meanwhile, the atropine in the composition has the activity of inhibiting ocular axis growth so as to delay the myopia progress; the compliance of a user can be effectively improved, and the continuity and the final effect of myopia control treatment are ensured.

To provide an ophthalmic composition of atropine that can be stored for a long period of time. [Solution] An ophthalmic composition having a pH of about 4.2 to about 6.4 and comprising about 0.001 wt% to about 0.05 wt% of atropine or a pharmaceutically acceptable salt thereof, glycerin, and water, wherein after two weeks under storage conditions at 40°C and 75% relative humidity, the ophthalmic composition contains, based on the initial concentration, at least about 80%, at least about 85%, at least about 90%, at least about 93%, at least about 95%, at least about 97%, at least about 98%, or at least about 99% of the atropine or a pharmaceutically acceptable salt thereof.

The present invention provides ophthalmic acceptable formulations of atropine and other muscarinic acetylcholine receptor antagonists, which can be heat sterilized without significant degradation of the muscarinic acetylcholine receptor antagonists. The formulations are less acidic than previous muscarinic acetylcholine receptor antagonist ocular formulations, making them more comfortable when administered to the eye.

The invention discloses a photoetching ultrastructure multifunctional lens for preventing and delaying myopia, which comprises a lens main body, and a functional area is arranged in the lens main body. Compared with the prior art, the ultra-micro lens has the advantages that the ultra-micro lens forms a dense negative out-of-focus signal interference area, when eyes rotate, light passing through the area can generate irregular dynamic changes in different states of convergence, divergence and the like, meanwhile, the light is diffused at gap composite points of the photoetching ultra-micro lens, and the light intensity is improved. By means of the comprehensive design, the intensity of the negative defocus signals reaching the retina can be weakened to the maximum extent, the brain is prevented from receiving the negative defocus signals possibly accelerating myopia development, and then the effect that myopia occurrence and development are delayed in a nearly non-inductive mode is achieved. For the photophobia phenomenon occurring when low-concentration atropine is used for preventing and controlling myopia, a color-changing film layer can be additionally arranged to adjust the brightness of light rays entering eyes so as to relieve symptoms.